Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoints in clinical trials. This article describes the work of the Neurocognitive Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration. The goal of this committee is to identify standardized and specific cognitive assessment tools for use in NF clinical trials. The committee first identified cognitive domains relevant to NF1 and prioritized attention as the first domain of focus given prior and current trends in NF1 cognitive clinical trials. Performance measures and behavioral rating questionnaires of attention were reviewed by the group using established criteria to assess patient characteristics, psychometric properties, and feasibility. The highest rated tests underwent side-by-side comparison. The Digit Span subtest from the Wechsler scales was given the highest ratings of the performance measures due to its good psychometrics, feasibility, utility across a wide age range, and extensive use in previous research. The Conners scales achieved the highest ratings of the behavioral questionnaires for similar reasons. Future articles will focus on other cognitive domains, with the ultimate goal of achieving agreement for cognitive endpoints that can be used across NF clinical trials. Neurology ® 2016;87 (Suppl 1):S21-S30 GLOSSARY ADHD-RS 5 ADHD Rating Scale; CAARS 5 Conners Adult ADHD Rating Scale; COA 5 clinical outcome assessment; DS 5 Digit Span; FDA 5 Food and Drug Administration; FSIQ 5 full-scale IQ; MATRICS 5 Measurement and Treatment Research to Improve Cognition in Schizophrenia; NF1 5 neurofibromatosis type 1; ObsRO 5 observer-reported outcome; PerfO 5 performance outcome; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis; TEA 5 Test of Everyday Attention; TEA-Ch 5 Test of Everyday Attention for Children.
et al. 12 Animal models have provided guidance in the development of clinical trials, providing pathway level hypotheses for translation to human trials. 13 However, the translation from mouse behavior to human cognitive models has been challenging due to the range and complexity of human cognition and the lack of consensus regarding how best to measure cognition for clinical trials endpoints.
The diversity of approaches to measurement of cognitive outcomes is illustrated when reviewing the cognitive clinical trials that have been completed or are ongoing. As of 2016, there have been 9 clinical trials targeting cognitive outcomes in NF1, each employing a different battery of cognitive tests despite targeting the same primary constructs of attention, working memory, visual memory, intelligence, and emotional/behavioral functioning (table 1). The lack of evaluative and analytic consistency and standards significantly hinders our ability to adequately assess therapeutic efficacy, to combine smaller samples to yield higher power to detect effects, and limits the generalizability of findings.
Other disease groups have developed consensus and standards for evaluating cognitive outcomes to support the development of new therapies. 14, 15 Perhaps the most successful work in this area has been the work of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) collaboration. [15] [16] [17] The MATRICS group posited that the lack of approved treatments for cognitive dysfunction in schizophrenia was directly related to the use of diverse assessment approaches across clinical trials. This problem significantly limited the ability to adequately evaluate a drug's effectiveness in treating cognitive deficits, especially for governmental organizations tasked with oversight. 15 The MATRICS group identified specific criteria critical for determining appropriate assessment tools for endpoints in clinical trials of schizophrenia, including (1) good test-retest reliability, (2) high utility for repeated assessment, (3) a relationship with functional outcomes, (4) sensitivity to a pharmacologic agent, and (5) practicality. 15 Co-primary endpoints that assess the impact of cognitive functioning on everyday living skills were also emphasized. These measures complement the primary outcome of cognitive performance and provide essential evidence of therapeutic utility.
Following the example of other diseasespecific groups, this article is the first of its kind to provide recommendations for cognitive outcomes for clinical trials in NF1. This will support the promotion of cognition as a target for interventions in NF1 and encourage the development of novel compounds and behavioral therapies targeting these impairments.
CONSIDERATIONS AND CHALLENGES There are challenges associated with efficiently and effectively developing a standardized cognitive test battery for use in clinical trials. First, there are many cognitive domains that could conceivably be appropriate for clinical trials endpoints and within many of these domains are subdomains of skills, each of which has the potential to be a specific therapeutic target (table 2) . For example, full-scale IQ (FSIQ) is composed of multiple distinct functional areas including verbal and nonverbal reasoning, working memory/attention, and processing speed. Given the multifactorial nature of intellect, global measures such as FSIQ will likely lack the sensitivity to be ideal primary endpoints, particularly when there are discrepancies between the various functions assessed, as is common in NF1.
Second, many tests are available to assess each cognitive domain. Each test varies in its reliability and validity for specific populations, as well as its feasibility for use in clinical trials, including use for shorter test-retest periods. Developmental factors are another significant challenge for cognitive researchers. Few cognitive tests or symptom checklists are intended to span broad age ranges, with most meant for specific use with preschoolers, school-age children/adolescents, or adults. It will be important to include young children in clinical trials; however, preschool measures are sparse compared to those available for other age ranges, and will require careful consideration. Finally, there is virtually no literature about cognitive effects of aging in NF1, such that it is unclear which measures are most effective at characterizing cognitive functioning in older adulthood. Based on these considerations, we prioritized the domain of attention, a highly prevalent problem in NF1, which has been evaluated in recent or ongoing clinical and preclinical trials. Further, the current work will focus on school-aged children ($6 years) through adults. We will review and make recommendations for the preschool age group, as well as offer methodologic and statistical approaches to longitudinal designs across age groups (e.g., preschool into school age, and school age into adulthood), in future publications.
METHODS

Goals of the REiNS Neurocognitive
Committee. The goals of this working group are to (1) critically and scientifically review standardized cognitive assessment tools for use in NF1 clinical trials, (2) provide recommendations for a core test bank of neurocognitive measures across cognitive domains to be utilized in NF1 clinical trials to enhance consistency across trials and sites, and (3) function as a resource for researchers in the development of cognitive protocols. By providing this guidance, we hope to support the development and evaluation of novel therapeutics for the treatment of cognitive deficits in children and adults with NF1.
Food and Drug Administration (FDA) clinical outcome assessment (COA). To select clinically useful cognitive endpoints, we have been guided by recommendations regarding COAs. 18 These COAs must be appropriately defined and reliable for the evaluation of a specific condition of interest in a specific context of use, based on available evidence. Qualification as a COA indicates that a tool can be relied upon to measure a distinct concept and have a specific interpretation and application in drug development. The FDA has deemed 2 areas of specific relevance: performance outcome (PerfO) and observer-reported outcome (ObsRO) assessments. PerfO fall into 2 categories: (1) paper-pencil tests and (2) computerized tasks/batteries. ObsRO include behavior rating questionnaires completed by caretakers (parents, guardians) and teachers, which assess a child's behavioral/emotional functioning or cognitive functions including attention, impulsivity, executive function, and adaptive function, in their everyday environment. Within each of the cognitive domains being evaluated, we provide recommendations for both performance and observational measures, which may serve as co-primary outcome tools in NF1 clinical trials to evaluate their impact on everyday function, as has been recommended by the FDA. 19 Current clinical trials. We completed a literature search for past and current pharmacologic cognitive clinical trials in NF1 in order to summarize the literature and document the diversity of assessment instruments utilized for the same or very similar primary outcome constructs. We performed several searches to include PubMed.gov and ClinicalTrials.gov. Using the search terms "neurofibromatosis type 1 cognitive clinical trial" and "neurofibromatosis type 1 methylphenidate" identified 8 current or complete/published trials. We were made aware of a ninth pharmacologic trial that was accepted for publication but ahead of print, which was included.
Identification of cognitive domains and tools for review.
Because of the extensive number of cognitive domains and associated assessment tools, it would be prohibitive to complete an exhaustive review of all published tests. In order to increase the feasibility of achieving the goals of the working group, a 2-step process was implemented. The first phase involved identifying all cognitive domains relevant to NF1 and prioritizing those domains, with the highest importance associated with the known or likely targets for cognitive clinical trials now and in the near future. The second phase included surveying experienced NF1 cognitive researchers and clinicians, who were asked to list the assessment instruments within each cognitive domain that they use most consistently and consider to be reliable and sensitive tools with the NF1 population. The list of potential assessment tools was summarized and discussed to establish a final pool of instruments to be reviewed in order to establish a core set of test instruments. This manuscript provides recommendations for Executive function An umbrella term for higher-order cognitive processes involved in managing cognitive and behavioral resources to achieve a goal Initiation; inhibition; monitoring (cognitive and behavioral); working memory; strategic planning; organization; flexibility; emotional regulation
Memory
The ability to retain and recall information Encoding; consolidation; retrieval; (verbal and visual; short-and long-term)
Processing speed
The ability to complete tasks quickly, automatically, and fluently
Visual-spatial/visual-motor Visual-spatial skills include the ability to mentally manipulate 2D and 3D objects, as well as determine spatial relationships between objects; visual-motor skills are the ability to coordinate motor movements with visual input Mental rotation; visual closure; spatial orientation; object localization; form/pattern discrimination; drawing/copying
Language
Receptive language skills are the ability to understand language heard or read; expressive language skills are the ability to put thoughts into words and sentences in a way that makes sense and is grammatically correct Phonology-phonemic awareness, decoding, encoding (spelling and reading); semantics-receptive (aural and written-to include reading comprehension); expressive (oral and written-to include spelling and composition); morphology-understanding and producing grammatical aspects of language; pragmaticsunderstanding social aspects of language; using social language appropriately; syntax-understanding and using appropriate sentence structure Children and Wechsler Adult Intelligence Scale), the Test of Everyday Attention (TEA), and the TEA for Children (TEA-Ch). [23] [24] [25] [26] The TEA-Ch and DS have both been used in previous published clinical trials with NF1 and demonstrated adequate psychometric properties. As the TEA-Ch includes 9 different subtests, we evaluated this measure in several ways: as a complete battery including all 9 subtests, as a screening instrument of 4 subtests (Sky Search, Score!, Creature Counting, and Sky Search Dual Task), and as individual subtests. We reviewed the TEA as a complete battery as well as by individual subtests, particularly as they relate to continuity with the TEA-Ch. These measures were then compared across the primary evaluative factors. Although the TEA-Ch (and the TEA, the adult version of the test) is a feasible and sensitive assessment of attention, it lacks normative data in individuals 16 and 17 years of age. In prior studies, this gap has resulted in arbitrary truncation of inclusion criteria related to age. 27 In addition, there is a lack of parallel subtests between the TEA-Ch and TEA, significantly limiting the use of these tools across age ranges in clinical trials. For these reasons, the committee could not recommend the tools as primary outcome measures in NF1 clinical trials.
DS can be used as a combined performance score, or separated into Forward, Backward, and Sequencing components. The committee ultimately chose DS as the recommended PerfO measure of attention given its utility in a wide range of ages (6 years through adult), good feasibility (easily administered in sites that have a Wechsler instrument), as well as good psychometric properties, particularly test-retest reliability. Because DS Backward and Sequencing tap into aspects of executive function including working memory, the committee recommends the specific use of DS Forward for the measurement of attention. When using any performance-based test in preintervention and postintervention designs, the risk of practice effects must always be considered. Previous intervention trials using DS have found limited Table 3 Review and rating process of cognitive tests and rating scales Test-retest r 5 0.85 (parent); r 5 0.85 (teacher); r 5 0.79 (self-report); interrater r 5 0.81 (parent); r 5 0.73 (teacher)
Confirmatory factor analyses revealed parent and self-reports have adequate fit; teacher version was slightly lower; acceptable betweeninformant correlations: parent to teacher r 5 0.60; parent to self-report r 5 0.56; teacher to self-report r 5 0.48; convergent and divergent validity established with other measures of child and adolescent psychopathology; moderate to high discriminant validity reported in the manual for the different scoring version of the Conners 3; probability of accurately predicting group membership (e.g., ADHD vs non-ADHD, impulsive vs hyperactive vs combined) ranged from 0.66 to 0.95
Previous version (CRS-R) has been used in 16 clinical trials (PubMed search term: Conners' Rating Scales-Revised); CRS-R has been used in many cross-sectional studies, including NF1 47 ; Scoring options for DSM-5 and DSM-IV-TR Current version has limited use in published clinical trials to date 2.65 CAARS 33 2,000 181 (observer and self-report)
Test-retest r 5 0.80-0.91 (self-report); r 5 0.85-0.95 (observer) 33 Confirmatory factor analyses for both selfreport and observer forms met criteria for good fit; was able to discriminate between ADHD and control group with an overall correct classification rate of 85%; construct validity examined using the WURS, r 5 0.37-0. practice effects in as short as a 6 week test-retest time span, suggesting that DS can be used even over short intervals. 28, 29 However, practice effects should always be managed through study methodology (e.g., inclusion of a control group) or statistical approaches, such as the use of reliable change indices, which take into account psychometric issues, practice effects, and other sources of variance to ensure that change demonstrated on tests is meaningful. 30 In addition, the DS, like many tests, has a truncated range of scores that may limit the ability to detect change for individuals who are not impaired at baseline. Researchers will need to take these considerations into account when using this measure as a clinical trial endpoint.
Five observation attention scales were reviewed (table 5). The 2 measures with the highest ratings were the Conners scales and the ADHD Rating Scale (ADHD-RS). 31 The Conners scales include 2 versions: the Conners Parent Rating Scale-3 (ages 6 through 18) and the Conners Adult ADHD Rating Scale (CAARS; age 18 and older). 32, 33 Similarly, the ADHD-RS has child and adult rating forms. The Vanderbilt ADHD Rating Scale was also considered, but limitations related to a severely truncated age range, limited use in studies generally, regionally limited normative data, and lack of age-based standard scores removed the instrument from further consideration.
In comparing the Conners scales and the ADHD-RS, both received similar ratings. However, the committee believed that the superior psychometric information available and the extensive use of the prior version of the Conners scales in clinical trials were significant advantages and the Conners scales were therefore chosen for recommendation. In addition, the Connors scales have options for multiple informants for both the child and adult scales, adding to their reliability in multiple settings. For school-aged children, options include a parent, teacher, and selfreport questionnaire. For adults, options include a self-report and an observer report. Additionally, the Conners scales have extensive psychometric data available and provide subscales beyond attentiondeficit symptomatology that are of interest and importance in NF, including learning problems, executive function, and peer relations (table 4) . However, caution is warranted in using the executive function subscale as a primary outcome variable as it only correlated significantly with the Plan/Organize scale of the Behavior Rating Inventory of Executive Function. 33 DISCUSSION AND FUTURE DIRECTIONS The establishment of recommendations for a rigorously reviewed core test bank of cognitive tests for use in NF clinical trials is of vital importance given the morbidity these deficits cause in individuals with NF1 and the increased focus from the scientific community on the development of targeted therapies to ameliorate these impairments. To date, there has been no systematic review of the psychometric properties of available cognitive assessment tools specifically for use in clinical trials in NF1. As we work to promote the development of novel therapies targeting cognition in this population, it is imperative that we prioritize this step. To that end, the REiNS Neurocognitive Committee has taken a systematic, detailed approach to reviewing available tests of cognition in order to be able to make recommendations for performance-and observer-based instruments in clinical trials targeting cognitive deficits. We have taken guidance from the FDA in our approach, with the identification of and regulatory approval of cognitive enhancing agents for NF1 in mind. In this article, we focused on paper-pencil tools assessing attention, and our extensive review led us to recommend DS from the Wechsler scales as the performance-based outcome measure, and the Conners scales (Conners 3 for children; CAARS for adults) as the observer-rated outcome measure. The recommendations being made are to establish a core set of tests for use in clinical trials, but are not meant to preclude individual researchers' ability to include other tests relevant to the specific research hypotheses in the battery of outcome measures for any given trial. Future articles will provide recommendations for computerized batteries (including tests of attention) and tests in other key domains, including executive function, memory, academic skills, and others.
No single instrument will capture all aspects of a complex domain or function ideally for all trial designs. However, the DS and Connors scales represent the ObsRO and PerfO tools that have been reviewed so far with the best combination of psychometric properties, patient characteristics, and feasibility for NF1 clinical trials currently available. Adoption of these measures in clinical trials of cognitive outcomes in NF1 will support the development of novel therapeutics for cognitive dysfunction in NF1 and lead to improved impact through the use of consistent, reliable, and sensitive cognitive outcome measures.
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